PHILADELPHIAConsumption of alcohol has long been associated with an increased risk of advanced liver fibrosis, but a new study published online in Clinical Infectious Diseases from researchers at Penn Medicine and other institutions shows that association is drastically heightened in people co-infected with both HIV and chronic hepatitis C virus (HCV) infection. Even light ("nonhazardous") drinkingwhich typically poses a relatively low risk for uninfected personswas linked to an increased risk of liver fibrosis in the co-infected group.
Reasons for this are not fully understood, but preclinical studies have shown that the two viruses can induce liver cell death and that adding alcohol may accelerate that process and more quickly lead to severe liver fibrosis. Toxicity to the liver from antiretroviral drugs may also be exacerbated by alcohol.
"We've shown a much greater risk for coinfected compared to uninfected persons at all levels of alcohol consumptionfrom nonhazardous drinking up to hazardous/binge drinking and abuse/dependence," said senior author Vincent Lo Re III, MD, MSCE, assistant professor of Medicine and Epidemiology in the division of Infectious Diseases and department of Biostatistics and Epidemiology at Penn and an infectious disease physician at the Veteran Affairs Medical Center in Philadelphia. "This highlights how important it is for clinicians to be counseling co-infected patients on reducing alcohol consumption. More communication and education about the risks of alcohol may prompt patients to reduce drinking or quit altogether, which will help reduce the incidence of complications."
Few studies have investigated the association between alcohol and liver disease in HIV/HCV-co-infected patients, and none have compared risks to uninfected persons.
For the study, researchers, which included first author Joseph K. Lim, MD, of the Yale University School of Medicine and the Veterans Affairs Connecticut Healthcare System, conducted a cross-sectional study among 7,270 participants from the Veterans Aging Cohort Study: 701 HIV/HCV co-infected; 1,410 HIV-mono-infected; 296 HCV-mono-infected; and 1,158 uninfected. Alcohol use was determined by the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaire and diagnoses of alcohol abuse/dependence and classified as nonhazardous drinking, hazardous/binge drinking, and alcohol-related diagnosis.
The team found that regardless of HIV or HCV status, the prevalence of advanced hepatic fibrosis increased as alcohol use category increased. However, the strongest associations were observed in co-infected patients across all alcohol categories compared with uninfected non-hazardous drinkers.
Co-infected individuals with nonhazardous drinking were 13 times more likely to have advanced liver fibrosis than uninfected persons who reported non-hazardous drinking. Co-infected patients with a history of hazardous/binge drinking were 17 times more likely, whereas those who had alcohol-related diagnosis were 21 times more likely, to have advanced liver fibrosis compared to their uninfected non-hazardous drinking counterparts.
"The difference between co-infected and uninfected groups was stark. Given the prevalence of drinking in co-infected individuals, it is important to determine the patterns of alcohol use, such as nonhazardous drinking and even binge drinking, which are not traditionally thought to contribute to liver fibrosis," said Lo Re.
|Contact: Steve Graff|
University of Pennsylvania School of Medicine